Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Princeton, New Jersey
- Most recent report
- 10-Q, filed Oct 29, 2026
- Incorporated
- Delaware
- Filings on record
- 1,004+ filings
- On EDGAR
- CIK 14272
- Fiscal year ends
- December
- Filer status
- Large accelerated filer
Financials 8 of 31
News 8 of 125
Prospectuses and Registrations 8 of 27
- S-8 Registration statement for an employee plan May 8, 2026
- 424B5 Prospectus supplement for an offering Nov 7, 2025
- FWP Free writing prospectus Nov 5, 2025
- 424B2 Prospectus supplement for an offering Nov 3, 2025
- 25-NSE Notice that a security was delisted May 15, 2025
- S-3ASR Automatic shelf registration Dec 13, 2024
- 424B5 Prospectus supplement for an offering Feb 16, 2024
- FWP Free writing prospectus Feb 15, 2024
Proxies 8 of 29
- DEFA14A Extra proxy material Apr 17, 2026
- DEFA14A Extra proxy material Mar 25, 2026
- DEF 14A Proxy statement for a shareholder vote Mar 25, 2026
- DEFA14A Extra proxy material Apr 15, 2025
- DEFA14A Extra proxy material Mar 26, 2025
- DEF 14A Proxy statement for a shareholder vote Mar 26, 2025
- DEFA14A Extra proxy material Apr 22, 2024
- DEFA14A Extra proxy material Mar 28, 2024
Ownership 8 of 713
- 4 Insider reported a trade Nov 6, 2026
- 144 Notice of a proposed sale of restricted stock Nov 6, 2026
- 4 Insider reported a trade Nov 4, 2026
- 4 Insider reported a trade Nov 3, 2026
- 4 Insider reported a trade Nov 3, 2026
- 4 Insider reported a trade Nov 3, 2026
- 4 Insider reported a trade Oct 5, 2026
- 4 Insider reported a trade Oct 2, 2026
Other 8 of 79
- 11-K Employee stock plan report Jun 5, 2026
- 11-K Employee stock plan report Jun 5, 2026
- 11-K Employee stock plan report Jun 5, 2026
- 15-12G Mar 27, 2026
- ARS Annual report sent to shareholders Mar 25, 2026
- CERT Exchange certified a listing Nov 12, 2025
- 8-A12B Registration of a security for exchange listing Nov 10, 2025
- POSASR Oct 31, 2025
What to read: Sep 2026 10-Q
SECSift found 2 of 11 sections worth reading, with 0 positive, 1 notable, and 6 negative flags.
Financial Statements (Item 1)
Financial statements and notes with material balance-sheet, debt, and IPRD details.Negative- IRS proposed adjustments for 2008-2012 tax years remain unresolved; appeals process ongoing, could be material.
- Receivables from three largest U.S. customers represent 71% of trade receivables at Sep 2026, high concentration.
- IPRD impairment charges of $830M recorded in R&D for nine months ended Sep 2026, reflecting partial write-downs of two assets.
Management's Discussion (Item 2)
MD&A with detailed product revenue, expense, and liquidity data; IRA and tariff risks quantified.
What changed: Sep 2026 vs. Jun 2026
About 11% of BMY's Sep 2026 10-Q is new information. 39 paragraphs were added, 186 changed, and 47 removed. Below are the most important lines SECSift identified.
Changed
Removed
- Abbreviation 'NHL Non-Hodgkin's Lymphoma' was removed from the summary.
- Abbreviation 'sNDA supplemental New Drug Application' was removed from the summary.
- Exhibit 10a (2026 Stock Award and Incentive Plan) was removed from the exhibit list.
- The line 'The Exhibits designated by the symbol ‡‡ are management contracts or compensatory plans or arrangements.' was removed.
Everything here comes from Bristol Myers Squibb Co's own filings on SEC EDGAR. The filing list is rechecked every hour. SECSift analysis was completed on Oct 29, 2026, from the 10-Q for Sep 2026.